Biovac to manufacture and distribute Pfizer-BioNtech Covid-19 vaccine doses within Africa
21 July 2021
Cape Town based, specialist biotech company, Biovac, has been appointed to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union, making it the first company in Africa to produce an mRNA-based vaccine.
Biovac is set to immediately commence technical transfer activities, which includes on-site development and equipment installation activities. Biovac will obtain drug substance from facilities in Europe, and manufacturing of finished doses will commence in 2022. At full operational capacity, the annual COVID-19 vaccine production will exceed 100 million finished doses annually. All doses will exclusively be distributed within the 55 member states that make up the African Union. Biovac expects the facility will be brought into the Pfizer-BioNTech supply chain by the end of 2021.